AdCLD-CoV19

AdCLD-CoV19
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Routes of
administration		Intramuscular

AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,[1][2][3] a company from South Korea.[4]

References

  1. ↑ "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers". ClinicalTrials.gov. 14 December 2020. NCT04666012. Retrieved 23 March 2021.
  2. ↑ Chan-Hyuk, Kim (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review. Retrieved 22 August 2021.
  3. ↑ Chan-hyuk, Kim (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review. Retrieved 22 August 2021.
  4. ↑ Cellid Co Ltd, Company Profile and News, Bloomberg Markets.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.